Regulatory

Regulatory Watch

Regulatory status of peptide compounds across the FDA, TGA, EMA, and WADA, with coverage of approvals, scheduling decisions, and guidance from the authorities governing peptide therapeutics.

Is it legal? Peptide status by jurisdiction

How the peptides tracked here are classified in each major jurisdiction, and which are prohibited in sport. Each page lists every tracked compound and its recorded status, with links to the cited profile.

Regulatory coverage

Recent reporting on approvals, regulatory filings, and scheduling decisions affecting peptide compounds.

Regulatory status by compound

How each tracked peptide is classified by major regulators and anti-doping authorities. Colored dots indicate the regulatory tone of an entry; the text states its specific status.

Status keyApprovedInvestigationalRestricted / Rx-onlyProhibitedUnclear
  • Tirzepatide

    Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide)

    Approved
    United States (FDA)
    Approved. Mounjaro for type 2 diabetes (May 2022); Zepbound for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024).
    Australia (TGA)
    Registered on the ARTG (Mounjaro) for type 2 diabetes and for weight management, available on prescription.
    European Union (EMA)
    Authorized (Mounjaro) for type 2 diabetes and weight management (marketing authorization granted September 2022).
    WADA
    Not prohibited. Added to the WADA 2026 Monitoring Program, with markers tracked in- and out-of-competition to detect patterns of misuse; not a banned substance.
  • Semaglutide

    Glucagon-like peptide-1 (GLP-1) receptor agonist

    Approved
    United States (FDA)
    Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
    Australia (TGA)
    Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
    European Union (EMA)
    Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
    WADA
    Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
  • PT-141 (Bremelanotide)

    Melanocortin receptor agonist; synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH)

    Approved
    United States (FDA)
    Approved June 21, 2019 as Vyleesi (bremelanotide) for acquired, generalized HSDD in premenopausal women; prescription medicine.
    Australia (TGA)
    Not registered on the ARTG; no approved bremelanotide/Vyleesi product in Australia. Compounded or imported PT-141 is unapproved.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU (European commercialisation rights licensed to Gedeon Richter were terminated in 2016 and no EU approval followed).
    WADA
    Not specifically named on the WADA Prohibited List. As an approved medicine it is not captured by the S0 non-approved-substances clause, and it does not fall within a listed prohibited class; athletes should nonetheless verify current status.
  • Liraglutide

    Glucagon-like peptide-1 (GLP-1) receptor agonist (acylated GLP-1 analogue)

    Approved
    United States (FDA)
    Approved. Victoza for type 2 diabetes (2010), with a cardiovascular risk reduction indication added in 2017; Saxenda (liraglutide 3.0 mg) for chronic weight management (2014), later extended to adolescents aged 12 to 17 with obesity (2020).
    Australia (TGA)
    Registered on the ARTG: Victoza for type 2 diabetes and Saxenda for weight management, available on prescription.
    European Union (EMA)
    Authorized: Victoza (2009) for type 2 diabetes and Saxenda (2015) for weight management.
    WADA
    Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.
  • Dulaglutide

    Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment)

    Approved
    United States (FDA)
    Approved. Trulicity for type 2 diabetes (2014); an indication to reduce major adverse cardiovascular events in adults with type 2 diabetes was added in 2020.
    Australia (TGA)
    Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.
    European Union (EMA)
    Authorized (Trulicity) for type 2 diabetes (marketing authorization granted 2014).
    WADA
    Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.
  • Exenatide

    Glucagon-like peptide-1 (GLP-1) receptor agonist; synthetic exendin-4

    Approved
    United States (FDA)
    Approved. Byetta (exenatide twice daily) for type 2 diabetes (2005), the first GLP-1 receptor agonist approved, and Bydureon (extended-release, once weekly) (2012).
    Australia (TGA)
    Registered on the ARTG for type 2 diabetes, available on prescription.
    European Union (EMA)
    Authorized: Byetta (2006) and Bydureon (2011) for type 2 diabetes.
    WADA
    Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.
  • Mazdutide

    Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors; a synthetic oxyntomodulin analogue

    Approved
    China (NMPA)
    Approved. China's National Medical Products Administration approved mazdutide in 2025, first for chronic weight management in adults with overweight or obesity and subsequently for glycemic control in adults with type 2 diabetes (Innovent Biologics).
    United States (FDA)
    Investigational in the United States; not approved. Developed and studied predominantly in China (Innovent Biologics, in-licensed from Eli Lilly).
    Australia (TGA)
    Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
    European Union (EMA)
    Not authorized; investigational, no marketing authorization.
    WADA
    Not listed on the WADA Prohibited List. As an incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.
  • Orforglipron

    Oral small-molecule (non-peptide) agonist of the glucagon-like peptide-1 (GLP-1) receptor

    Approved
    United States (FDA)
    Approved. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, based on the ATTAIN Phase 3 program. A type 2 diabetes indication (ACHIEVE program) is not yet approved.
    Australia (TGA)
    Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
    European Union (EMA)
    Not authorized; no marketing authorization at this time.
    WADA
    Not listed on the WADA Prohibited List. As a GLP-1 receptor agonist it is not a banned substance.
  • Tesamorelin

    Synthetic analogue of growth hormone-releasing hormone (GHRH); approved for HIV-associated lipodystrophy

    Approved
    United States (FDA)
    Approved. Egrifta (tesamorelin) approved in November 2010 to reduce excess abdominal fat in HIV-infected patients with lipodystrophy; reformulated products (Egrifta SV, Egrifta WR) were subsequently approved for the same indication.
    Australia (TGA)
    Not registered on the Australian Register of Therapeutic Goods (ARTG); no approved tesamorelin product in Australia.
    European Union (EMA)
    No EMA marketing authorisation; tesamorelin is not an approved medicine in the European Union.
    WADA
    Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth-hormone-releasing factors, including GHRH and its analogues such as tesamorelin, are prohibited. Athletes require a therapeutic use exemption.
  • Afamelanotide

    Synthetic linear analogue of alpha-melanocyte-stimulating hormone (alpha-MSH); melanocortin-1 receptor (MC1R) agonist ([Nle4-D-Phe7]-alpha-MSH, NDP-MSH)

    Approved
    United States (FDA)
    Approved October 2019 as Scenesse (afamelanotide) implant to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP); a prescription medicine administered by a physician.
    Australia (TGA)
    Approved by the TGA and registered on the Australian Register of Therapeutic Goods (ARTG) in November 2020 as Scenesse (afamelanotide) implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria; sponsored by the Australian company Clinuvel Pharmaceuticals.
    European Union (EMA)
    Authorised in 2014 as Scenesse for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria.
    WADA
    Not specifically named on the WADA Prohibited List; as an approved medicine used for a rare photodermatosis it does not fall within a listed prohibited class.
  • Gonadorelin

    Synthetic gonadotropin-releasing hormone (GnRH/LHRH); decapeptide identical to endogenous GnRH; GnRH receptor agonist

    Approved
    United States (FDA)
    Has a history of FDA approval: gonadorelin hydrochloride (Factrel) for evaluating pituitary gonadotropic function and gonadorelin acetate (Lutrepulse) for pulsatile induction of ovulation in hypothalamic amenorrhea. Several branded products have since been discontinued in the US (not for safety reasons), and gonadorelin is now commonly supplied via pharmacy compounding.
    Australia (TGA)
    Gonadorelin (native GnRH) has historically been used in Australia for diagnostic and fertility indications; whether a gonadorelin-specific product is currently on the ARTG is unclear. Related GnRH analogues such as leuprorelin and goserelin are registered.
    European Union (EMA)
    Gonadorelin has been marketed in European countries through national approvals (as a diagnostic agent and for pulsatile fertility therapy) rather than through a single centralised EMA authorisation.
    WADA
    Prohibited in males under Section S2: WADA lists gonadotropin-releasing hormone (GnRH) agonists among luteinising-hormone releasing factors, and gonadorelin is explicitly named; it is not prohibited in females.
  • Elamipretide

    Mitochondria-targeted tetrapeptide (cardiolipin-binding Szeto-Schiller peptide)

    Approved
    United States (FDA)
    Granted accelerated approval on September 19, 2025 as Forzinity (elamipretide HCl) to improve muscle strength in adult and paediatric patients with Barth syndrome who weigh at least 30 kg, based on an intermediate endpoint (knee-extensor muscle strength) with a confirmatory trial required. It is not approved for any other indication, and the pivotal primary mitochondrial myopathy trial (MMPOWER-3) did not meet its primary endpoint.
    Australia (TGA)
    Not on the ARTG; investigational only and not approved for supply.
    European Union (EMA)
    No EMA marketing authorisation; not authorised as a medicine in the EU.
    WADA
    Not listed by name on the Prohibited List; athletes should verify current status with their anti-doping organisation.
  • Setmelanotide

    Melanocortin-4 receptor (MC4R) agonist

    Approved
    United States (FDA)
    Approved. Initial U.S. approval November 2020 for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing. The label was later extended to Bardet-Biedl syndrome (2022), to children as young as 2 years (2024), and to acquired hypothalamic obesity in patients 4 years and older (2026).
    Australia (TGA)
    Not registered on the Australian Register of Therapeutic Goods (ARTG). Any access in Australia would be through unapproved-goods pathways such as the Special Access Scheme.
    European Union (EMA)
    Authorized. Marketing authorisation valid throughout the EU since 16 July 2021 for weight management in patients 6 years and older with obesity due to POMC, PCSK1 or LEPR deficiency, and Bardet-Biedl syndrome.
    WADA
    Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide among metabolic agents). An MC4R agonist is not prohibited in or out of competition.
  • Pramlintide

    Synthetic amylin analog (amylinomimetic)

    Approved
    United States (FDA)
    Approved. Initial U.S. approval 2005 (Symlin, NDA 021332) as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have failed to achieve glycemic control despite optimal insulin therapy. The label carries a boxed warning for insulin-induced severe hypoglycemia.
    Australia (TGA)
    Not registered on the Australian Register of Therapeutic Goods (ARTG); pramlintide is not marketed as a registered medicine in Australia.
    European Union (EMA)
    Not authorized. Pramlintide does not hold an EMA marketing authorisation and is not marketed in the European Union.
    WADA
    Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program. An amylin analog is not prohibited in or out of competition.
  • Lixisenatide

    Short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-4 based incretin mimetic)

    Approved
    United States (FDA)
    Approved as Adlyxin (NDA 208471) in July 2016 for adults with type 2 diabetes. Sanofi discontinued US sales and the standalone product was withdrawn from the US market in early 2023 for commercial reasons, not safety. The fixed-ratio insulin glargine combination Soliqua remains marketed.
    Australia (TGA)
    Registered on the ARTG as Lyxumia in 2013 as a prescription-only medicine. Sanofi cancelled the standalone Lyxumia ARTG entry in February 2021.
    European Union (EMA)
    Authorised as Lyxumia on 1 February 2013 for type 2 diabetes. The marketing authorisation was withdrawn on 18 December 2025 at Sanofi's request for commercial reasons. The insulin glargine combination Suliqua remains authorised.
    WADA
    Not listed as a prohibited substance on the WADA Prohibited List (2026). GLP-1 receptor agonists are not classified as prohibited in or out of competition.
  • Teriparatide

    Recombinant human parathyroid hormone fragment PTH(1-34); bone-forming (anabolic) osteoporosis agent

    Approved
    United States (FDA)
    Approved as Forteo (NDA 021318) on 26 November 2002, the first anabolic osteoporosis agent, for postmenopausal women and men at high fracture risk and, later, glucocorticoid-induced osteoporosis.
    Australia (TGA)
    Registered on the ARTG (Forteo, ARTG 80333) as a prescription medicine; teriparatide biosimilars such as Terrosa are also registered.
    European Union (EMA)
    Authorised as Forsteo on 10 June 2003 (Eli Lilly Nederland B.V.) for osteoporosis in postmenopausal women, men at increased fracture risk, and glucocorticoid-induced osteoporosis. Teriparatide biosimilars are also authorised.
    WADA
    Not listed as a prohibited substance on the WADA Prohibited List (2026). Parathyroid hormone analogs are not classified as prohibited in or out of competition.
  • Abaloparatide

    Synthetic parathyroid hormone-related protein (PTHrP 1-34) analog; osteoanabolic agent

    Approved
    United States (FDA)
    Approved. Postmenopausal women with osteoporosis at high risk of fracture (April 2017, brand Tymlos); expanded to men with osteoporosis at high risk of fracture (December 2022).
    Australia (TGA)
    Registered on the ARTG as a prescription medicine (Eladynos, sponsor Theramex Australia) for postmenopausal osteoporosis, November 2024.
    European Union (EMA)
    Authorised across the EU (Eladynos) for postmenopausal osteoporosis, December 2022, following an earlier 2018 refusal.
    WADA
    Not listed on the WADA Prohibited List; parathyroid hormone analogs are not among the prohibited peptide-hormone classes.
  • Octreotide

    Synthetic somatostatin analog (octapeptide); inhibitor of growth hormone and gastroenteropancreatic hormone secretion

    Approved
    United States (FDA)
    Approved. Acromegaly, plus symptoms associated with metastatic carcinoid tumors and VIPomas (Sandostatin, 1988); a long-acting depot form (Sandostatin LAR) is also approved.
    Australia (TGA)
    Registered on the ARTG as a prescription medicine (Sandostatin and Sandostatin LAR).
    European Union (EMA)
    Authorised and marketed in EU member states (nationally authorised; brand Sandostatin).
    WADA
    Not listed on the WADA Prohibited List; somatostatin analogs are not among the prohibited peptide-hormone classes.
  • Lanreotide

    Long-acting synthetic somatostatin analog (cyclic octapeptide)

    Approved
    United States (FDA)
    Approved. Acromegaly (Somatuline Depot, August 2007); gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival (December 2014); carcinoid syndrome (2017).
    Australia (TGA)
    Registered on the ARTG as a prescription medicine (Somatuline Autogel, sponsor Ipsen), since September 2003.
    European Union (EMA)
    Authorised and marketed in EU member states (nationally authorised; brand Somatuline Autogel).
    WADA
    Not listed on the WADA Prohibited List; somatostatin analogs are not among the prohibited peptide-hormone classes.
  • Teduglutide

    Recombinant glucagon-like peptide-2 (GLP-2) analog

    Approved
    United States (FDA)
    Approved. Gattex (teduglutide) for adults with short bowel syndrome who are dependent on parenteral support, December 2012; use later extended to pediatric patients.
    Australia (TGA)
    Registered on the ARTG as Revestive (ARTG 274911) since May 2017 for adults with short bowel syndrome dependent on parenteral support; prescription medicine.
    European Union (EMA)
    Authorized. Revestive (teduglutide) received an EU-wide marketing authorisation in August 2012 for short bowel syndrome.
    WADA
    Not listed on the WADA Prohibited List.
  • Desmopressin

    Synthetic vasopressin V2-receptor agonist analog (1-deamino-8-D-arginine vasopressin)

    Approved
    United States (FDA)
    Approved. First approved in 1978 (DDAVP); labelled indications include central diabetes insipidus, hemostasis in mild hemophilia A and von Willebrand disease, primary nocturnal enuresis, and nocturia due to nocturnal polyuria (Nocdurna).
    Australia (TGA)
    Registered on the ARTG (Minirin and other brands; tablet, nasal spray, sublingual wafer, and injection) for indications including diabetes insipidus and nocturnal enuresis; prescription medicine.
    European Union (EMA)
    Authorized nationally across EU member states (not via a centralized EMA marketing authorisation).
    WADA
    Prohibited at all times. Listed as a masking agent under Section S5 (Diuretics and Masking Agents) of the Prohibited List.
  • Linaclotide

    Guanylate cyclase-C (GC-C) agonist peptide (14 amino acids)

    Approved
    United States (FDA)
    Approved. Linzess (linaclotide) for adults with irritable bowel syndrome with constipation and with chronic idiopathic constipation, August 2012.
    Australia (TGA)
    Registered on the ARTG as Constella (linaclotide) for adults with IBS-C and chronic idiopathic constipation; prescription medicine.
    European Union (EMA)
    Authorized. Constella (linaclotide) received an EU-wide marketing authorisation in November 2012 for irritable bowel syndrome with constipation in adults.
    WADA
    Not listed on the WADA Prohibited List.
  • Retatrutide

    Triple agonist of the GIP, GLP-1, and glucagon receptors (investigational incretin/metabolic peptide)

    Investigational
    United States (FDA)
    Investigational; not approved. Phase 3 TRIUMPH program ongoing, with a first positive topline readout (TRIUMPH-4) reported in December 2025.
    Australia (TGA)
    Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
    European Union (EMA)
    Not authorized; investigational, no marketing authorization.
    WADA
    Not listed on the WADA Prohibited List. As an investigational incretin-class agent it is not a banned substance; the closely related approved GLP-1 agonists are on WADA's monitoring program rather than prohibited.
  • Cagrilintide

    Long-acting amylin (and calcitonin) receptor agonist / amylin analogue

    Investigational
    United States (FDA)
    Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.
    Australia (TGA)
    Not entered on the ARTG; investigational only and not approved for supply.
    European Union (EMA)
    Not authorized; investigational, no marketing authorization.
    WADA
    Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.
  • KPV

    Tripeptide (Lys-Pro-Val); C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH); melanocortin-derived anti-inflammatory peptide

    Investigational
    United States (FDA)
    Not FDA-approved; was on the 503A Category 2 list, removed April 2026, and scheduled for Pharmacy Compounding Advisory Committee review (July 2026). On July 23, 2026, the committee voted 8-6, with one abstention, to recommend KPV (for wound treatment and inflammatory conditions) for the Section 503A Bulk Drug Substances List; the vote is advisory and non-binding, and the FDA had not made a final decision as of publication.
    Australia (TGA)
    No registered/approved product; an unapproved therapeutic substance.
    European Union (EMA)
    No EMA marketing authorisation.
    WADA
    Not specifically named on the Prohibited List.
  • Epithalon

    Synthetic pineal tetrapeptide bioregulator (Ala-Glu-Asp-Gly / AEDG); studied as a telomerase-related peptide

    Investigational
    United States (FDA)
    Not FDA-approved for any indication. Historically placed on the FDA 503A Category 2 bulk drug substances list (substances with significant safety concerns) restricting pharmacy compounding; subject of ongoing FDA compounding review in 2026. On July 24, 2026, the Pharmacy Compounding Advisory Committee voted 7-4, with one abstention, to recommend epitalon (for insomnia) for the Section 503A Bulk Drug Substances List; the vote is advisory and non-binding, and the FDA had not made a final decision as of publication.
    Australia (TGA)
    Not approved by the TGA and not entered on the Australian Register of Therapeutic Goods (ARTG); no registered therapeutic product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Not listed by name on the Prohibited List, but unapproved peptides of this type are generally captured by the S0 'Non-Approved Substances' category (any pharmacological substance with no current approval by a governmental health authority for human therapeutic use), which is prohibited at all times. Athletes should treat it as prohibited.
  • Selank

    Synthetic tuftsin analog (heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro); anxiolytic/nootropic neuropeptide

    Investigational
    United States (FDA)
    Not FDA-approved. Selank acetate was removed from the FDA 503A 'Category 2' bulk drug substances list on September 20, 2024 after the nomination was withdrawn; it is not part of the ongoing 2026 FDA compounding review.
    Australia (TGA)
    Not approved by the TGA and not on the ARTG; no registered therapeutic product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Not listed by name; because it lacks approval by major (stringent) regulatory authorities, it is generally treated as captured by the S0 'Non-Approved Substances' category, prohibited at all times. Athletes should treat it as prohibited.
  • Semax

    Synthetic ACTH(4-10) analog (heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro); nootropic/neuroprotective neuropeptide

    Investigational
    United States (FDA)
    Not FDA-approved; unscheduled. Historically placed on the FDA 503A Category 2 bulk drug substances list (significant safety concerns) restricting compounding; part of ongoing 2026 FDA compounding review. On July 24, 2026, the Pharmacy Compounding Advisory Committee voted 8-5 to recommend semax (for cerebral ischemia, migraine and trigeminal neuralgia) for the Section 503A Bulk Drug Substances List; the vote is advisory and non-binding, and the FDA had not made a final decision as of publication.
    Australia (TGA)
    Not approved by the TGA and not on the ARTG; no registered therapeutic product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Not listed by name; because it lacks approval by major (stringent) regulatory authorities, it is generally treated as captured by the S0 'Non-Approved Substances' category, prohibited at all times. Athletes should treat it as prohibited.
  • Survodutide

    Dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors (investigational metabolic peptide)

    Investigational
    United States (FDA)
    Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH.
    Australia (TGA)
    Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
    European Union (EMA)
    Not authorized; investigational, no marketing authorization.
    WADA
    Not listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.
  • Hexarelin

    Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP) hexapeptide

    Investigational
    United States (FDA)
    Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
    Australia (TGA)
    Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues and growth hormone-releasing peptides (GHRPs) are explicitly covered.
  • GHRP-2

    Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; growth hormone-releasing peptide (GHRP)

    Investigational
    United States (FDA)
    Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
    Australia (TGA)
    Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    Japan (PMDA)
    Approved as a diagnostic agent (pralmorelin) used to evaluate growth hormone secretory capacity; not approved as a therapeutic treatment.
    WADA
    Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues including GHRP-2 are explicitly covered.
  • GHRP-6

    Synthetic growth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist; first-described growth hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys)

    Investigational
    United States (FDA)
    Not approved for any indication; an unapproved growth hormone secretagogue with no marketed product.
    Australia (TGA)
    Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth hormone secretagogues including GHRP-6 are explicitly covered.
  • Follistatin

    Endogenous activin-binding glycoprotein; myostatin/activin antagonist (studied as recombinant protein and via gene therapy, e.g., FS-344)

    Investigational
    United States (FDA)
    Not approved for any indication; follistatin-based gene therapies have been studied only in early-phase clinical trials.
    Australia (TGA)
    Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered therapeutic product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Prohibited at all times under Section S4.3 (Agents preventing activin receptor IIB activation), which explicitly names follistatin among myostatin-binding proteins; gene-therapy delivery may additionally be captured under M3 (Gene and Cell Doping).
  • Kisspeptin

    Reproductive neuropeptide; KISS1 gene product and endogenous agonist of the kisspeptin receptor (KISS1R/GPR54); upstream stimulator of GnRH neurons

    Investigational
    United States (FDA)
    Not approved for any indication; investigational and studied only in clinical research.
    Australia (TGA)
    Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered therapeutic product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Prohibited in males under Section S2: WADA added kisspeptin to the 2024 Prohibited List as an example of a testosterone-stimulating peptide (a luteinising-hormone releasing factor); it is prohibited in males only, not in females.
  • Humanin

    Mitochondrial-derived peptide (24-residue; encoded in the mtDNA 16S rRNA region); cytoprotective

    Investigational
    United States (FDA)
    Not FDA-approved; a research/experimental peptide with no approved therapeutic use.
    Australia (TGA)
    Not on the ARTG; an unapproved experimental substance.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Not listed by name on the Prohibited List; as a non-approved substance, athletes should verify current status with their anti-doping organisation.
  • DSIP

    Delta sleep-inducing peptide; endogenous neuromodulatory nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)

    Investigational
    United States (FDA)
    Not FDA-approved; an experimental peptide with no approved therapeutic use. On July 24, 2026, the FDA Pharmacy Compounding Advisory Committee voted 6-7, with one abstention, against recommending emideltide, the delta sleep-inducing peptide nominated under the DSIP name, for the Section 503A Bulk Drug Substances List, citing insufficient safety and efficacy data for insomnia, narcolepsy and opioid use disorder; it was the only one of seven nominated peptides not recommended.
    Australia (TGA)
    Not on the ARTG; an unapproved experimental substance.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Not listed by name on the Prohibited List; as a non-approved substance, athletes should verify current status with their anti-doping organisation.
  • LL-37

    Human cathelicidin antimicrobial peptide (37-residue C-terminal fragment of hCAP18); host-defence peptide

    Investigational
    United States (FDA)
    Not FDA-approved; an endogenous human peptide studied in early-stage research and not an approved drug.
    Australia (TGA)
    Not on the ARTG; no approved LL-37 product.
    European Union (EMA)
    No EMA marketing authorisation; investigated only in early clinical studies (for example, wound healing).
    WADA
    Not listed by name on the Prohibited List; as an endogenous host-defence peptide it is not a named prohibited substance, but synthetic administration is unapproved and athletes should verify current status.
  • Dihexa

    Angiotensin IV-derived peptide (metabolically stabilised); investigational nootropic / HGF-Met modulator

    Investigational
    United States (FDA)
    Not FDA-approved; an experimental nootropic peptide with no approved therapeutic use.
    Australia (TGA)
    Not on the ARTG; an unapproved experimental substance.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Not named on the Prohibited List, but as a non-approved substance it is captured by S0 (Non-Approved Substances), prohibited at all times; athletes should treat it as prohibited.
  • FOXO4-DRI

    Senolytic peptide (FOXO4 D-retro-inverso peptide); disrupts the FOXO4-p53 interaction

    Investigational
    United States (FDA)
    Not FDA-approved; an experimental senolytic peptide with no approved therapeutic use, and preclinical only.
    Australia (TGA)
    Not on the ARTG; an unapproved experimental substance.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Not named on the Prohibited List, but as a non-approved substance it falls under S0 (Non-Approved Substances), prohibited at all times; athletes should treat it as prohibited.
  • Maridebart cafraglutide

    Peptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activity

    Investigational
    United States (FDA)
    Not approved. Investigational only; in clinical development for obesity and type 2 diabetes and not authorized for any indication.
    Australia (TGA)
    Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.
    European Union (EMA)
    Not authorized. Investigational; no EU marketing authorisation.
    WADA
    Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).
  • Amycretin

    Unimolecular GLP-1 and amylin receptor co-agonist

    Investigational
    United States (FDA)
    Not approved. Investigational only; in early-to-mid phase clinical development for obesity and not authorized for any indication.
    Australia (TGA)
    Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.
    European Union (EMA)
    Not authorized. Investigational; no EU marketing authorisation.
    WADA
    Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).
  • Efpeglenatide

    Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly)

    Investigational
    United States (FDA)
    Not approved. Efpeglenatide remains an investigational agent with no FDA marketing authorization.
    Australia (TGA)
    Not registered on the ARTG. Investigational only.
    European Union (EMA)
    Not authorised. No EMA marketing authorization.
    WADA
    Not listed as a prohibited substance on the WADA Prohibited List (2026). GLP-1 receptor agonists are not classified as prohibited in or out of competition.
  • Petrelintide

    Long-acting amylin (islet amyloid polypeptide) receptor agonist for weight management

    Investigational
    United States (FDA)
    Not approved. Investigational and in clinical development for chronic weight management.
    Australia (TGA)
    Not registered on the ARTG. Investigational only.
    European Union (EMA)
    Not authorised. Investigational only.
    WADA
    Not listed as a prohibited substance on the WADA Prohibited List (2026). Amylin analogs are not classified as prohibited in or out of competition.
  • BPC-157

    Synthetic stable gastric pentadecapeptide (15-amino-acid partial sequence derived from a protein in human gastric juice)

    Restricted / Rx-only
    United States (FDA)
    Not FDA-approved; barred from pharmacy compounding as a 503A Category 2 bulk drug substance (2023); no approved human indication. On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend BPC-157 (for ulcerative colitis) for the Section 503A Bulk Drug Substances List; the vote is advisory and non-binding, and the FDA had not made a final decision as of publication.
    Australia (TGA)
    Schedule 4 (Prescription Only Medicine) under the Poisons Standard (added to Schedule 4 effective 1 June 2024); no registered product, prescription/compounded supply only.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine.
    WADA
    Prohibited at all times under S0 (non-approved substances) since 2022; no therapeutic use exemption available.
  • Melanotan II

    Synthetic cyclic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH); non-selective melanocortin receptor agonist

    Restricted / Rx-only
    United States (FDA)
    Not approved for any use; the FDA treats melanotan II as an unapproved new drug that is marketed illegally, including as an injectable tanning product.
    Australia (TGA)
    Not on the Australian Register of Therapeutic Goods (ARTG); melanotan I and II are unapproved substances, and the TGA has warned consumers against unapproved injectable tanning products. Supply for therapeutic use falls in the prescription-only class.
    European Union (EMA)
    No EU marketing authorisation. Melanotan II is an unlicensed product; European medicines regulators, including the UK's MHRA, have issued public safety warnings, and its sale is illegal in the UK.
    WADA
    Not specifically named on the WADA Prohibited List; melanocortin receptor agonists are not a listed prohibited class. As an unapproved substance, athletes should nonetheless verify its current status.
  • TB-500

    Synthetic peptide fragment (Ac-LKKTETQ) corresponding to the actin-binding region of thymosin beta-4; note it is NOT the same molecule as full-length recombinant thymosin beta-4

    Prohibited
    United States (FDA)
    Not FDA-approved; TB-500 placed on the 503A Category 2 list (barred from compounding). Full-length thymosin beta-4 (RGN-259) is a separate investigational drug in Phase 3 ophthalmic trials. On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend TB-500 (for wound healing) for the Section 503A Bulk Drug Substances List; the vote is advisory and non-binding, and the FDA had not made a final decision as of publication.
    Australia (TGA)
    No registered/approved product; an unapproved therapeutic substance.
    European Union (EMA)
    No EMA marketing authorisation.
    WADA
    Prohibited at all times under S2 (peptide hormones, growth factors and mimetics) since 2011.
  • CJC-1295

    Growth hormone-releasing hormone (GHRH) analog

    Prohibited
    United States (FDA)
    Not approved for any indication and never marketed. FDA placed CJC-1295 in Category 2 (potential significant safety risk) of the interim 503A bulk drug substances list; the nomination was later withdrawn/removed and the Pharmacy Compounding Advisory Committee did not recommend it for the 503A bulks list.
    Australia (TGA)
    Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved GHRH analog. Supply for human therapeutic use is restricted (prescription-only class of substance) and no obesity/GH indication is approved.
    European Union (EMA)
    No EMA marketing authorization; not an approved medicine in the EU.
    WADA
    Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); GHRH analogues including CJC-1295 are explicitly listed.
  • Ipamorelin

    Growth hormone secretagogue; ghrelin (GHS-R1a) receptor agonist (pentapeptide)

    Prohibited
    United States (FDA)
    Not approved for any indication. FDA removed ipamorelin acetate from Category 2 of the interim 503A bulks list (September 2024) after the nomination was withdrawn and did not add it to the compoundable 503A list; PCAC review did not support inclusion.
    Australia (TGA)
    Not on the ARTG; an unapproved growth hormone secretagogue. Supply for human therapeutic use is restricted (prescription-only class) with no approved indication.
    European Union (EMA)
    No EMA marketing authorization; not an approved medicine in the EU.
    WADA
    Prohibited at all times under Section S2; growth hormone secretagogues including ipamorelin are explicitly listed.
  • MOTS-c

    Mitochondrial-derived peptide (MDP); AMPK activator / exercise mimetic

    Prohibited
    United States (FDA)
    Not approved for any indication; an experimental peptide with no FDA-approved therapeutic use, and not an approved/compoundable drug substance. On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted 7-5, with two abstentions, to recommend MOTS-c (for obesity and osteoporosis) for the Section 503A Bulk Drug Substances List; the vote is advisory and non-binding, and the FDA had not made a final decision as of publication.
    Australia (TGA)
    Not on the ARTG; an unapproved experimental substance with no approved indication.
    European Union (EMA)
    No EMA marketing authorization; not an approved medicine in the EU.
    WADA
    Prohibited at all times under Section S4.4 (Metabolic Modulators), 4.4.1 Activators of AMP-activated protein kinase (AMPK); MOTS-c is explicitly named. No therapeutic use exemption is available because there is no approved therapeutic use.
  • AOD-9604

    Modified C-terminal fragment of human growth hormone (tyrosine-modified hGH 176-191); lipolytic peptide

    Prohibited
    United States (FDA)
    Not approved as a drug; no New Drug Application and no approval for any indication. It holds self-affirmed GRAS (Generally Recognized As Safe) status as a food/dietary-supplement ingredient (a safety designation only, not an efficacy or drug approval). In 2024-2026 FDA compounding actions it was treated as a Category 2 substance, i.e. not eligible for 503A pharmacy compounding.
    Australia (TGA)
    Not approved for therapeutic use; the obesity indication was not approved. When supplied for therapeutic use it is a prescription-only (Schedule 4) substance; it is not an approved medicine on the ARTG.
    European Union (EMA)
    No EMA marketing authorization; not an approved medicine in the EU.
    WADA
    Prohibited at all times under Section S2; explicitly listed as a growth hormone fragment (alongside hGH 176-191).
  • IGF-1 LR3

    Long-acting insulin-like growth factor-1 analogue (Long R3 IGF-1); recombinant IGF-1 with an Arg3 substitution and a 13-amino-acid N-terminal extension; sold as a laboratory research reagent

    Prohibited
    United States (FDA)
    Not approved for any human use; marketed as a research-use-only reagent, not for human administration. It is a distinct molecule from the approved recombinant human IGF-1 drug mecasermin (Increlex).
    Australia (TGA)
    Not on the Australian Register of Therapeutic Goods (ARTG); an unapproved substance with no registered therapeutic product.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); insulin-like growth factor-1 (IGF-1) and its analogues are explicitly covered.
  • GHK-Cu

    Copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with Cu2+); endogenous matrikine; cosmetic ingredient name Copper Tripeptide-1

    Unclear
    United States (FDA)
    Not an approved drug; topical form regulated as a cosmetic ingredient (Copper Tripeptide-1); injectable GHK-Cu was on the 503A Category 2 list (2023) and removed in April 2026 after nominations were withdrawn.
    Australia (TGA)
    Permitted topically as a cosmetic ingredient; no approved medicinal (e.g., injectable) product.
    European Union (EMA)
    Permitted cosmetic ingredient (INCI: Copper Tripeptide-1); no medicinal marketing authorisation.
    WADA
    Not specifically named on the Prohibited List.
  • Sermorelin

    Synthetic analogue of growth hormone-releasing hormone comprising its first 29 amino acids (GHRH 1-29); formerly FDA-approved (Geref), later withdrawn from the US market

    Unclear
    United States (FDA)
    Previously approved as Geref (sermorelin acetate) for the diagnosis and treatment of growth hormone deficiency; the product was discontinued and withdrawn from the US market around 2008 for commercial reasons, not because of safety or efficacy concerns. No FDA-approved sermorelin product is currently marketed; it is available in the US only through pharmacy compounding.
    Australia (TGA)
    Not registered on the Australian Register of Therapeutic Goods (ARTG); no approved sermorelin product. Supply for human therapeutic use would be prescription-only or via compounding.
    European Union (EMA)
    No current EMA marketing authorisation; not an approved medicine in the European Union.
    WADA
    Prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics); growth-hormone-releasing factors, including GHRH and its analogues such as sermorelin, are prohibited.
  • Thymosin Alpha-1

    Synthetic 28-amino-acid thymic peptide (thymalfasin); immunomodulator

    Unclear
    United States (FDA)
    Not FDA-approved for any indication; remains investigational in the United States despite approval in many other countries, and has been the subject of US clinical study and orphan-drug interest without a marketing approval.
    China (NMPA) and other markets
    Approved and marketed as thymalfasin (Zadaxin) in China and numerous other countries (reportedly more than 30) for chronic hepatitis B and C and as an immune-system adjuvant, with additional local uses such as adjunctive care in sepsis and some cancers. Prescription medicine where approved.
    Australia (TGA)
    Not entered on the Australian Register of Therapeutic Goods (ARTG); no approved thymalfasin product in Australia.
    European Union (EMA)
    No EMA centralized marketing authorisation; not authorised as a medicine at the EU level.
    WADA
    Not listed by name on the WADA Prohibited List; as an immunomodulatory peptide it is not currently a named prohibited substance, though athletes should verify current status with their anti-doping organisation.
  • Thymalin

    Thymic polypeptide preparation (calf-thymus extract); immunomodulatory bioregulator

    Unclear
    United States (FDA)
    Not FDA-approved; no US marketing approval and not an approved medicine.
    Russia and former-Soviet states
    Registered and used clinically in Russia (and some neighbouring states) as an immunomodulatory thymic preparation; not evaluated or approved by the FDA, EMA or TGA.
    Australia (TGA)
    Not on the ARTG; an unapproved substance in Australia.
    European Union (EMA)
    No EMA marketing authorisation; not an approved medicine in the EU.
    WADA
    Not listed by name on the Prohibited List; its status as a peptide immunomodulator is not clearly defined for anti-doping purposes, and athletes should verify current status with their anti-doping organisation.
  • Argireline

    Topical cosmetic peptide (Acetyl Hexapeptide-8); SNAP-25 N-terminal fragment mimetic

    Unclear
    United States (FDA)
    Not an FDA-approved drug. Marketed as a topical cosmetic ingredient (INCI: Acetyl Hexapeptide-8); cosmetic ingredients are not subject to FDA pre-market approval, and no therapeutic (drug) claims are authorised.
    Australia (TGA)
    Permitted in topical cosmetics as a cosmetic ingredient; not an approved therapeutic (medicinal) product.
    European Union (EMA)
    Permitted as a cosmetic ingredient (INCI: Acetyl Hexapeptide-8) under EU cosmetics regulation; no medicinal marketing authorisation.
    WADA
    Not listed on the Prohibited List; a topical cosmetic peptide with no relevance to sport doping.

Regulatory classifications change; entries reflect the status recorded in each compound profile and are provided for reference, not as legal or medical advice.